. 2019 Feb 7;9:1561. doi: 10.1038/s41598-018-38248-1

Table 4.

Comparisons of Optical Coherence Tomography Angiography Parameters in Resolved and Persistent DME after intravitreal aflibercept.

	Resolved DME (n = 17)	Persistent DME (n = 6)	P value
CRT before treatment (µm) (mean ± SD)	471 ± 118	489 ± 141	0.778
Microaneurysm before treatment, no. (%)
SCP	3 (18)	1 (17)	1
DCP	14 (82)	6 (100)	0.539
Vessel area within 3 × 3 mm² before treatment (mm²)
SCP (mean ± SD)	3.802 ± 0.393	3.868 ± 0.358	0.723
DCP (mean ± SD)	3.890 ± 0.572	3.859 ± 0.529	0.911
FAZ area within 3 × 3 mm² before treatment (mm²)
SCP (mean ± SD)	0.442 ± 0.193	0.331 ± 0.197	0.244
DCP (mean ± SD)	0.757 ± 0.354	0.735 ± 0.311	0.894
CRT after treatment (µm) (mean ± SD)	249 ± 38	348 ± 61	<0.001
Microaneurysm after treatment, no. (%)
SCP	1 (6)	1 (17)	0.462
DCP	7 (41)	6 (100)	0.019
Vessel area within 3 × 3 mm² after treatment (mm²)
SCP (mean ± SD; range)	3.826 ± 0.372	3.799 ± 0.413	0.883
DCP (mean ± SD; range)	3.902 ± 0.647	3.887 ± 0.585	0.961
FAZ area within 3 × 3 mm after treatment (mm²)
SCP (mean ± SD; range)	0.512 ± 0.242	0.371 ± 0.195	0.216
DCP (mean ± SD; range)	0.690 ± 0.348	0.755 ± 0.285	0.684
LogMAR BCVA after treatment (mean ± SD)	0.132 ± 0.208	0.210 ± 0.247	0.501
Visual gain*	+0.169 ± 0.188	+0.008 ± 0.09	0.031
Number of injections (mean ± SD)	2.6 ± 1.2	2.7 ± 1.8	0.774

BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; CRT, central retinal thickness; NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; SCP, superficial capillary plexus; DCP, deep capillary plexus; FAZ, foveal avascular zone; SD, standard deviation.

*The visual gain is the difference between LogMAR BCVA after treatment and before treatment.

Resolved or persistent DME was defined as having a CRT below 300 µm or over 300 µm, respectively, after intravitreal aflibercept injection.